SUPARTZ FX
Seikagaku Corp. · Decision date Aug 18, 2025
What did the FDA decide?
FDA records P980044/S064 as a supplement to PMA P980044, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 18, 2025.
FDA approval order statement
for the sharing of existing SUPARTZ device family manufacturing equipment in Preparation Building-4 in the SKK Takahagi Plant for the manufacture of the FHA-SUPARTZ device family using hyaluronic acid derived from bacterial fermentation
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Aug 18, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P980044/S064
- Regulatory pathway
- PMA supplement
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- Decision code
- OK30
- Decision date
- Aug 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980044. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980044 · Original PMA
SUPARTZ FX
P980044/S063 · Related supplement
SUPARTZ FX; VISCO-3
P980044/S064 received
Application receipt date recorded by FDA.
P980044/S064 · FDA decision
30-Day Notice
P980044/S065 · Related supplement
SUPARTZ FX; VISCO-3
P980044/S068 · Related supplement
SUPARTZ FX
P980044/S067 · Related supplement
SUPARTZ FX
Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SUPARTZ FXP980044 | Seikagaku Corp. | PMA approval | Jan 24, 2001 | FDA |
SUPARTZ FX; VISCO-3P980044/S063 | Seikagaku Corp. | PMA supplement | Jul 22, 2025 | FDA |
SUPARTZ FX; VISCO-3P980044/S065 | Seikagaku Corp. | PMA supplement | Dec 19, 2025 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gelsyn-3P110005/S015 | Ibsa Institut Biochimique SA | PMA supplement | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Seikagaku Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005
Sources and methodology
- Original FDA record: P980044/S064
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




